Demaegdt Heidi, Lenaerts Pieter-Jan, Swales Julie, De Backer Jean-Paul, Laeremans Hilde, Le Minh Tam, Kersemans Ken, Vogel Lotte K, Michotte Yvette, Vanderheyden Patrick, Vauquelin Georges
Research Group on Experimental Pharmacology, Department of Molecular and Biochemical Pharmacology, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Eur J Pharmacol. 2006 Sep 28;546(1-3):19-27. doi: 10.1016/j.ejphar.2006.07.005. Epub 2006 Jul 21.
Due to its high affinity for [(125)I]Angiotensin IV, cystinyl aminopeptidase (CAP) has recently been assigned as the 'angiotensin AT(4) receptor'. Since the aminopeptidase N (AP-N) activity is also susceptible to inhibition by Angiotensin IV, it might represent an additional target for this peptide. Based on [(125)I]Angiotensin IV binding and catalytic activity measurements, we compared the ligand interaction properties of recombinant human CAP and human AP-N. Both enzymes displayed distinct pharmacological profiles. Although their activity is inhibited by Angiotensin IV and LVV-hemorphin 7, both peptides are more potent CAP-inhibitors. On the other hand, substance P and l-methionine have a higher potency for AP-N. High affinity binding of [(125)I]Angiotensin IV to CAP occurs in the presence of chelators but not to AP-N in either the absence or presence of chelators. These differences were exploited to determine whether CAP and/or AP-N are present in different cell lines (CHO-K1, COS-7, HEK293, SK-N-MC and MDBK). We provide evidence that CAP predominates in these cell lines and that, comparatively, CHO-K1 cells display the highest level of this enzyme.
由于胱氨酰氨肽酶(CAP)对[(125)I]血管紧张素IV具有高亲和力,最近它被确定为“血管紧张素AT(4)受体”。由于氨肽酶N(AP-N)的活性也易受血管紧张素IV抑制,它可能是该肽的另一个作用靶点。基于[(125)I]血管紧张素IV结合和催化活性测量,我们比较了重组人CAP和人AP-N的配体相互作用特性。两种酶都表现出不同的药理学特征。虽然它们的活性受到血管紧张素IV和LVV-血啡肽7的抑制,但这两种肽都是更有效的CAP抑制剂。另一方面,P物质和L-甲硫氨酸对AP-N的抑制作用更强。在螯合剂存在的情况下,[(125)I]血管紧张素IV与CAP发生高亲和力结合,但在不存在或存在螯合剂的情况下,它与AP-N均不发生高亲和力结合。利用这些差异来确定不同细胞系(CHO-K1、COS-7、HEK293、SK-N-MC和MDBK)中是否存在CAP和/或AP-N。我们提供的证据表明,在这些细胞系中CAP占主导地位,相对而言,CHO-K1细胞中该酶的水平最高。